Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 6/20 | 0.44 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.42 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | PRLHR | P49683 | 9/20 | 0.40 |
| ▸ | NPFFR2 | Q9Y5X5 | 7/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311547 | 0.95 | CSNK2A2 (0.43) | VEGFACHRNA10CHRNA9CTNNB1SLC40A1 | |
| SCHEMBL29311757 | 0.95 | CSNK2A2 (0.43) | VEGFACHRNA10CHRNA9CTNNB1SLC40A1 | |
| SCHEMBL29311858 | 0.93 | KCNA3 (0.43) | VEGFACTNNB1SLC40A1PRLHRNPFFR2 | |
| SCHEMBL29311844 | 0.92 | APLNR (0.43) | VEGFACHRNA10CHRNA9CTNNB1SLC40A1 | |
| SCHEMBL26292629 | 0.91 | RAMP3 (0.47) | CHRNA10CHRNA9CTNNB1SLC40A1PRLHR | |
| SCHEMBL26292620 | 0.91 | RAMP3 (0.47) | CHRNA10CHRNA9CTNNB1SLC40A1PRLHR | |
| SCHEMBL29311793 | 0.87 | KCNA3 (0.43) | VEGFACTNNB1PRLHRNPFFR2INSR | |
| SCHEMBL29311773 | 0.87 | CXCR4 (0.41) | PRLHRINSRCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL26307010 | 0.86 | NPY2R (0.48) | CTNNB1PRLHRINSRCSNK2A2CSNK2B | |
| SCHEMBL26292602 | 0.86 | RAMP3 (0.49) | CTNNB1SLC40A1PRLHRCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | VEGFA 131/4885CHRNA10 4882/4885CHRNA9 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.